2-(5-phenyl-1H-imidazol-3-ium-3-yl)acetate | 767623-12-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(5-phenyl-1H-imidazol-3-ium-3-yl)acetate
• CAS: 767623-12-1
• 化学式: C₁₁H₁₀N₂O₂
• mdl: MFCD08668291
• 分子量: 202.213
• InChiKey: QRJDYIOTZDYGON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  59.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(5-phenyl-1H-imidazol-3-ium-3-yl)acetate 、 (R)-1-(1-(4-ethoxyphenyl)-4-phenyl-1H-imidazol-2-yl)-N-(2-(ethylsulfonyl)ethyl)ethan-1-amine 在 双(2-氧代-3-恶唑烷基)次磷酰氯 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 N-[(1R)-1-[1-(4-ethoxyphenyl)-4-phenylimidazol-2-yl]ethyl]-N-(2-ethylsulfonylethyl)-2-(4-phenylimidazol-1-yl)acetamide
  参考文献：
  名称：

  Design and optimization of imidazole derivatives as potent CXCR3 antagonists

  摘要：

  A series of imidazole derivatives have been designed and optimized for CXCR3 antagonism, pharmacokinetic properties, and reduced formation of glutathione conjugates. Our efforts led to the discovery of potent CXCR3 antagonists with good pharmacokinetic properties. These compounds are useful tools for in vivo studies of CXCR3 function. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.072

文献信息

• Macrolide antibiotics
  申请人：——

  公开号：US20040077557A1

  公开（公告）日：2004-04-22

  The present invention relates to 11,12 &ggr; lactone ketolides of formula (I) wherein R, R 1 , R 2 , R 3 are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及公式（I）中的11,12 &ggr;内酯酮类化合物，其中R、R1、R2、R3如本文所定义的，以及其药学上可接受的盐和溶剂化物，以及它们的制备方法及在人或动物体内治疗或预防全身或局部细菌感染中的应用。
• Macrolide Antibiotics
  申请人：ALIHODZIC Sulejman

  公开号：US20060211636A1

  公开（公告）日：2006-09-21

  The present invention relates to 11,12 γ lactone ketolides of formula (I) wherein R, R 1 , R 2 , R 3 are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及式(I)的11,12-γ内酯酮类化合物，其中R、R1、R2、R3如定义所述，以及其药学上可接受的盐和溶剂化物，以及其制备方法和在人或动物体内治疗或预防系统性或局部细菌感染的用途。
• MACROLIDE ANTIBIOTICS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1363925B1

  公开（公告）日：2006-11-15
• Design and optimization of imidazole derivatives as potent CXCR3 antagonists
  作者：Xiaohui Du、Xiaoqi Chen、Jeffrey T. Mihalic、Jeffrey Deignan、Jason Duquette、An-Rong Li、Bryan Lemon、Ji Ma、Shichang Miao、Karen Ebsworth、Timothy J. Sullivan、George Tonn、Tassie L. Collins、Julio C. Medina

  DOI：10.1016/j.bmcl.2007.11.072

  日期：2008.1

  A series of imidazole derivatives have been designed and optimized for CXCR3 antagonism, pharmacokinetic properties, and reduced formation of glutathione conjugates. Our efforts led to the discovery of potent CXCR3 antagonists with good pharmacokinetic properties. These compounds are useful tools for in vivo studies of CXCR3 function. (c) 2007 Elsevier Ltd. All rights reserved.